


36. European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. Available at: http://www.eugs.org/eng/EGS_guidelines.asp; Accessed 15.01.19.
37. Gazzard G, Konstantakopoulos E, Garway-Heath D, et al. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT. *Health Technol Assess*. 2019;23(31):1–120. <https://doi.org/10.3310/hta23310>.
38. Kotecha A, Crabb DP, Spratt A, Garway-Heath DF. The relationship between diurnal variations in intraocular pressure measurements and central corneal thickness and corneal hysteresis. *Invest Ophthalmol Vis Sci*. 2009;50(9):4229–4236.
39. King AJ, Hudson J, Fernie G, et al. Primary trabeculectomy for advanced glaucoma: pragmatic multicentre randomised controlled trial (TAGS). *BMJ*. 2021;373:n1014.
40. Bengtsson B, Lindén C, Heijl A, et al. The glaucoma intensive treatment study: interim results from an ongoing longitudinal randomized clinical trial. *Acta Ophthalmol*. 2022;100(2):e455–e462.
41. Realini T, Shillingford-Ricketts H, Burt D, Balasubramani GK. West Indies Glaucoma Laser Study (WIGLS): 1. 12-Month efficacy of selective laser trabeculoplasty in Afro-Caribbeans with glaucoma. *Am J Ophthalmol*. 2017;184:28–33.
42. Philippin H, Matayan E, Knoll KM, et al. Selective laser trabeculoplasty versus 0.5% timolol eye drops for the treatment of glaucoma in Tanzania: a randomised controlled trial. *Lancet Glob Health*. 2021;9(11):e1589–e1599.
43. Foulsham WS, Fu L, Tatham AJ. Prior rates of visual field loss and lifetime risk of blindness in glaucomatous patients undergoing trabeculectomy. *Eye (Lond)*. 2015;29(10):1353–1359.
44. Chen R, King AJ. Lifetime visual outcomes of patients undergoing trabeculectomy. *Br J Ophthalmol*. 2021;105(11):1566–1570.
45. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. *Arch Ophthalmol*. 2002;120(10):1268–1279.
46. Jones L, Garway-Heath DF, Azuara-Blanco A, Crabb DP. Are patient self-reported outcome measures sensitive enough to be used as end points in clinical trials? Evidence from the United Kingdom Glaucoma Treatment Study. *Ophthalmology*. 2019;126(5):682–689.

Pictures & Perspectives



Severe Unilateral Vision Loss in a 77-Year-Old Man

A 77-year-old man with mild headache and sudden vision loss (no light perception) in his right eye was referred for giant cell arteritis (GCA). Fundoscopy revealed chalky white optic disc edema, focal retinal edema, and 2 Hollenhorst plaques (HHP) in the distal arcades (Fig A). Choroidal filling was delayed (Fig B). Erythrocyte sedimentation rate was 12 mm/hr; C-reactive protein was 5.02 mg/dl (normal ≤ 5.00 mg/dl). Neuroimaging demonstrated subclinical infarcts (Fig C) and near complete right internal carotid artery occlusion (Fig D). Bilateral temporal artery biopsies were negative. When ophthalmic artery occlusion is suspected, the presence of HHP suggests a thromboembolic source rather than GCA (Magnified version of Fig A–D is available online at www.aaojournal.org).

VICTORIA SATTAROVA, MD, MSc¹

MICHAEL S. LEE, MD¹

ANNE S. ABEL, MD^{1,2}

¹Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota; ²Department of Ophthalmology, Hennepin Healthcare, Minneapolis, Minnesota